GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omega Therapeutics Inc (NAS:OMGA) » Definitions » Book Value per Share

Omega Therapeutics (Omega Therapeutics) Book Value per Share : $0.75 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Omega Therapeutics Book Value per Share?

Omega Therapeutics's book value per share for the quarter that ended in Mar. 2024 was $0.75.

During the past 12 months, Omega Therapeutics's average Book Value Per Share Growth Rate was -66.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

Omega Therapeutics's current price is $2.12. Its book value per share for the quarter that ended in Mar. 2024 was $0.75. Hence, today's PB Ratio of Omega Therapeutics is 2.83.

During the past 5 years, the highest P/B Ratio of Omega Therapeutics was 4.44. The lowest was 0.60. And the median was 2.30.


Omega Therapeutics Book Value per Share Historical Data

The historical data trend for Omega Therapeutics's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Omega Therapeutics Book Value per Share Chart

Omega Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Book Value per Share
-1.39 -2.08 4.20 2.20 1.05

Omega Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.24 1.74 1.38 1.05 0.75

Competitive Comparison of Omega Therapeutics's Book Value per Share

For the Biotechnology subindustry, Omega Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Omega Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Omega Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Omega Therapeutics's PB Ratio falls into.



Omega Therapeutics Book Value per Share Calculation

Omega Therapeutics's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(58.02-0.00)/55.15
=1.05

Omega Therapeutics's Book Value Per Share for the quarter that ended in Mar. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(41.35-0.00)/55.16
=0.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Omega Therapeutics  (NAS:OMGA) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Omega Therapeutics Book Value per Share Related Terms

Thank you for viewing the detailed overview of Omega Therapeutics's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Omega Therapeutics (Omega Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
20 Acorn Park Drive, Cambridge, MA, USA, 02140
Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using the epigenomic controllers, Omega is seeking to transform the practice of human medicine through highly selective and direct control of the human genome to treat and cure disease. It primarily operates in the U.S.
Executives
Michelle C Werner director C/O OMEGA THERAPEUTICS, INC., 20 ACORN PARK D, CAMBRIDGE MA 02140
Christian S Schade director MEDAREX, 707 STATE ROAD, PRINCETON NJ 08540
Richard A Young director, 10 percent owner C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE SUITE 300, CAMBRIDGE MA 02139
Flagship Pioneering Special Opportunities Fund Ii General Partner Llc 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Flagship Pioneering Fund Vii, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Flagship Pioneering Fund Vii General Partner Llc 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Rainer J. Boehm director C/O HUMANIGEN, INC., 1000 MARINA BOULEVARD, SUITE 250, BRISBANE CA 94005-1878
Joshua Reed officer: Chief Financial Officer C/O ALDEYRA THERAPEUTICS, INC., 131 HARTWELL AVENUE, SUITE 320, LEXINGTON MA 02421
Kevin Mcmanus officer: Chief Human Resources Officer C/O OMEGA THERAPEUTICS, INC., 20 ACORN PARK D, CAMBRIDGE MA 02140
Ling Zeng officer: See Remarks C/O DICERNA PHARMACEUTICALS, INC., 33 HAYDEN AVENUE, LEXINGTON MA 02421
Yan Moore officer: Chief Medical Officer C/O OMEGA THERAPEUTICS, INC., 20 ACORN PARK D, CAMBRIDGE MA 02140
David A Berry director C/O ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, SUITE 400, CAMBRIDGE MA 02142
Flagship Ventures Fund V General Partner Llc 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Roger Sawhney officer: Chief Financial Officer C/O OMEGA THERAPEUTICS, INC., 20 ACORN PARK D, CAMBRIDGE MA 02140
Flagship Pioneering Fund Vi General Partner Llc 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142

Omega Therapeutics (Omega Therapeutics) Headlines

From GuruFocus